Related Experiment Video

Updated: Aug 13, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Engineered antibodies act as targeted therapies in cancer treatment

Mani Mohindru1, Amit Verma

  • 1Albert Einstein College of Medicine Cancer Center, Bronx, New York, USA.

Indian Journal of Pediatrics
|January 5, 2006
PubMed

Insights

Cancer treatment faces challenges with chemotherapy effectiveness plateauing. Monoclonal antibodies offer targeted therapies with reduced toxicity, improving cancer cure rates and patient outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Chemotherapy effectiveness in cancer treatment has plateaued over the past two decades.
  • There is a critical need for more effective and less toxic cancer therapies.
  • Targeted therapies, such as monoclonal antibodies, show promise in overcoming these limitations.

Purpose of the Study:

  • To review the fundamental concepts driving the development of monoclonal antibodies for cancer treatment.
  • To discuss the current clinical status and applications of monoclonal antibodies in oncology.
  • To highlight specific examples of monoclonal antibodies and their supporting clinical trials.

Main Methods:

  • Review of scientific literature on monoclonal antibody development and cancer therapy.
  • Analysis of clinical trial data for key monoclonal antibodies in oncology.
  • Discussion of the mechanisms of action and clinical efficacy of selected antibodies.

Main Results:

  • Monoclonal antibodies provide targeted cancer therapy with potentially lower toxicity to normal tissues compared to traditional chemotherapy.
  • Specific antibodies like Rituximab, Trastuzumab, and Bevacizumab have demonstrated significant clinical utility in various cancers.
  • Key clinical trials have established the efficacy and safety profiles of these targeted agents.

Conclusions:

  • Monoclonal antibodies represent a significant advancement in targeted cancer therapeutics.
  • These agents offer improved efficacy and reduced toxicity, addressing the limitations of conventional chemotherapy.
  • Continued research and development in monoclonal antibody therapy are crucial for advancing cancer treatment strategies.

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...